Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.51 |
| ▸ | DPP4 | P27487 | 4/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.34 |
| ▸ | GRM6 | O15303 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31091497 | 0.89 | DPP4 (0.53) | DPP8DPP9DPP4BLMKMT2A | |
| SCHEMBL31680489 | 0.84 | PTGS1 (0.40) | DPP8DPP9DPP4PTGS1ALDH1A1 | |
| SCHEMBL30350525 | 0.83 | SLC1A3 (0.40) | DPP8DPP9DPP4PTGS1ALDH1A1 | |
| SCHEMBL31258939 | 0.82 | DPP7 (0.47) | DPP8DPP9DPP4PTGS1ALDH1A1 | |
| SCHEMBL29378289 | 0.81 | PTGS1 (0.42) | DPP8DPP9DPP4PTGS1ALDH1A1 | |
| SCHEMBL29666118 | 0.81 | PTGS1 (0.45) | BLMALOX15PTGS1ALDH1A1MAPT | |
| SCHEMBL29971461 | 0.80 | DPP7 (0.40) | DPP8DPP9DPP4KMT2APTGS1 | |
| SCHEMBL3491102 | 0.80 | ALDH1A1 (0.41) | DPP8DPP9DPP4PTGS1ALDH1A1 | |
| SCHEMBL31222374 | 0.80 | PTGS1 (0.41) | DPP8DPP9DPP4PTGS1ALDH1A1 | |
| SCHEMBL30350403 | 0.78 | SLC7A5 (0.48) | PTGS1ALDH1A1MAPTSLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | claimed |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | claimed |
| EP-4090670-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| CN-115298196-A | Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases | 詹森生物科技公司 | 2022-11-04 | — | — | CN | claimed |
| CN-115279782-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 詹森生物科技公司 | 2022-11-01 | — | — | CN | claimed |
| US-20220251142-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2022-08-11 | — | — | US | claimed |
| EP-3997105-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Protagonist Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| CN-114341161-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 领导医疗有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4613761-A9 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4613761-A2 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Janssen Biotech, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-11-21 | — | — | US | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-115298196-A | Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases | 詹森生物科技公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-115279782-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 詹森生物科技公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220251142-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2022-08-11 | — | — | US | disclosed |
| EP-3997105-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | Protagonist Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114341161-A | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases | 领导医疗有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220041658-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251142-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | DPP8 252/4885DPP9 175/4885DPP4 375/4885 |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | DPP8 252/4885DPP9 175/4885DPP4 375/4885 |
| US-12552836-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL17A, IL36G | DPP8 330/4885DPP9 437/4885DPP4 963/4885 |
| US-20220041658-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | DPP8 252/4885DPP9 175/4885DPP4 375/4885 |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | DPP8 252/4885DPP9 175/4885DPP4 375/4885 |
| US-20240383954-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | DPP8 252/4885DPP9 175/4885DPP4 375/4885 |
| US-20260116921-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, IL36G | DPP8 90/4885DPP9 172/4885DPP4 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.